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Edited by Hans EklundAbstract The X-ray crystal structure of Mycobacterium
tuberculosis shikimate kinase (SK) with bound shikimate and
adenosine diphosphate (ADP) has been determined to a resolu-
tion of 2.15 A. The binding of shikimate in a shikimate kinase
crystal structure has not previously been reported. The substrate
binds in a pocket lined with hydrophobic residues and interacts
with several highly conserved charged residues including Asp34,
Arg58, Glu61 and Arg136 which project into the cavity.
Comparisons of our ternary SK–ADP–shikimate complex with
an earlier binary SK–ADP complex show that conformational
changes occur on shikimate binding with the substrate-binding
domain rotating by 10. Detailed knowledge of shikimate
binding is an important step in the design of inhibitors of SK,
which have potential as novel anti-tuberculosis agents.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The shikimate pathway is a seven step biosynthetic pathway
which converts phosphoenolpyruvate and erythrose 4-phos-
phate to chorismate [1]. Chorismate is the major branch point
in the synthesis of vitamins E and K, folic acid, ubiquinone
and the essential aromatic a-amino acids [1]. Intermediates
also serve as substrates for other metabolic pathways. Shi-
kimate kinase (SK) (E.C. 2.7.1.71) catalyzes the ﬁfth step in the
shikimate pathway; phosphoryl transfer from adenosine tri-
phosphate (ATP) to shikimate, yielding shikimate-3-phos-
phate. The shikimate pathway is essential to higher plants,
fungi, algae, bacteria [1] and apicomplexan parasites [2], but is
absent in mammals. Therefore, this pathway is an attractive
target for the development of herbicides [3], antimicrobial* Corresponding author. Fax: +44-1865-287547.
E-mail address: daves@strubi.ox.ac.uk (D.K. Stammers).
Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphos-
phate; Ec, Escherichia coli; Erc, Erwinia chrysanthemi; Mt, Mycobac-
terium tuberculosis; SD, standard deviation; SK, shikimate kinase;
TAD, torsion angle diﬀerence
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doi:10.1016/j.febslet.2004.08.005agents [4], and antiparasite agents [2]. Mycobacterium tuber-
culosis (Mt) is one of the six microorganisms that account for
over 90% of infectious diseases, a leading cause of death
worldwide. The World Health Organisation reports that more
adults and adolescents die from Mt than any other single
infection [5].
Several SK crystal structures have previously been deter-
mined. Known SK structures include the Erwinia chrysant-
hemi (Erc) SK, unliganded and an MgADP complex [6];
Escherichia coli (Ec) SK I, unliganded [7]; Campylobacter
jejuni SK, unliganded (not published, PDB accession code
1VIA) and an MtSK MgADP complex [8]. Preliminary
NMR studies on Aquifex aeolicus SK have been reported [9].
However, no SK structure with bound shikimate has yet
been published. The work presented here reports the crystal
structure of MtSK with bound shikimate and describes as-
sociated conformational changes in the protein. Such
knowledge will be of use in the design of novel inhibitors of
shikimate kinase that may have potential as anti-mycobac-
terial drugs.2. Materials and methods
2.1. MtSK cloning, protein expression and puriﬁcation
A synthetic gene for MtSK based on the amino acid sequence re-
ported by Gu et al. [10] was made by Blue Heron Biotechnology
(Bothell, WA 98021, USA). The MtSK gene was initially cloned into
pUC19 and subsequently an NdeI–BamHI fragment containing the
gene was excised and ligated into pET17b. Expression of MtSK was
carried out in the Ec strain BL21(DE3) at 37 C using 100 lg/ml
ampicillin for selection and 0.2 mg/ml IPTG for induction.
Following cell harvesting, sonication and centrifugation the super-
natant was chromatographed on a DEAE Sephacel column equili-
brated with 50 mM potassium phosphate, pH 7.2, 150 mM NaCl and
1mM DTT. The ﬂow-through was subjected to an ammonium sulfate
cut (30% saturation). The precipitate was re-dissolved and loaded onto
a Sephacryl S-300 column and the ﬂow through collected. Active
fractions were identiﬁed by enzyme assay [8], analyzed by SDS–PAGE,
made 1.0 M in ammonium sulfate and further fractionated on a phenyl
Sepharose column.
2.2. Crystallization, data collection and structure determination
Prior to crystallization, MtSK was concentrated and buﬀer ex-
changed for 20 mM Tris–HCl, pH 7.4, 40 mM KCl, and 0.1% sodium
azide using Vivascience Vivaspin centrifugal concentrators. Pooled
concentrates were then ﬁltered through Amersham NAP 25 columns
and re-concentrated to 15 mg/ml.blished by Elsevier B.V. All rights reserved.
Table 1
Statistics for crystallographic structure determination
Wavelength (A) 1.5418
Space group P3221
Unit cell (A) a ¼ b ¼ 63:7, c ¼ 91:6
Unit cell (A) for 1L4Y a ¼ b ¼ 63:9, c ¼ 92:1
Resolution range (A) 30.0 – 2.15
Observations 72 430
Unique reﬂections 12 270
Completeness (%) 99.9
I=rI 22.4
Rmergea 0.075
Wilson B value 40.52
Outer resolution shell
Resolution range (A) 2.19–2.15
Unique reﬂections 606
Completeness (%) 100
I=rI 3.5
Rmergea 0.644
Reﬁnement statistics
Resolution range (A) 30.0–2.15
No. of reﬂections (working/test) 10 549/1256
R factorb (Rworking=Rfree) 0.218 (0.211/0.279)
No. of atoms (protein/water/others) 1216/119/42
rms Bond length deviation (A) 0.0084
rms Bond angle deviation () 1.48
Mean B factor (A2)c 49/53/53/49
rms Backbone B factor deviationd 3.6
aRmerge ¼
P jI  hIij=PhIi.
bR factor ¼P jFo  Fcj=
P
Fo:
cMean B factor for main-chain, side-chain, water and other ligands
(ADP, shikimate and chloride), respectively.
d rms Deviation between B factors for bonded main-chain atoms.
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adenosine diphosphate (ADP), and 5 mM shikimic acid (Sigma) and/
or 5 mM MgCl2, an initial crystallization screen of 480 conditions was
carried out by the sitting drop vapor diﬀusion method. 200 nl drop
sizes (1:1 protein/precipitant ratio) were set up using a Cartesian robot
[11]. Based on the results obtained, further larger scale optimization
screens were set up. Crystals grew from 0.5 M lithium chloride, 0.1 M
Tris–HCl, pH 7–9, and 10–20% (w/v) PEG of various average mo-
lecular weights (PEG 2000–8000). The best diﬀracting crystals grew in
the absence of magnesium. The crystal morphology improved signiﬁ-
cantly using lower molecular weight PEG as precipitant. Crystals
grown from PEG 2000 were found to be of suﬃcient quality for X-ray
diﬀraction experiments.
Crystals of MtSK were ﬂash-cooled to 100 K and data collected
using Cu Ka radiation (k ¼ 1:5418 A) from a Rigaku RU200H ro-
tating anode generator and a 30 cm MAR image plate. The data were
processed using the HKL (version 1.96.1) suite of programs [12]. Data
collection and reﬁnement statistics are shown in Table 1.
The MtSK crystals are of the same space group as previously re-
ported by Gu et al. [8,10], but with a slight change in each unit cell
length (Table 1). The MtSK–MgADP binary structure (PDB acces-
sion code: 1L4Y) was used as a starting model in order to solve the
ternary MtSK structure by the CNS suite of programs [13]. Initially,
two rounds of rigid-body reﬁnement followed by simulated annealing
were performed. Cycles of positional and individual B-factor reﬁne-
ment, with bulk solvent correction followed. The model was rebuilt to
include water molecules and chloride ions using the molecular
graphics program O [14]. Electron density maps showed unambiguous
Fo  Fc density for both ADP and shikimate, which were added to the
model during the later stages of reﬁnement. The shikimate molecule
was built using the molecular modeling program HyperChem v7.0
(Hypercube, Inc). The CNS parameter and topology ﬁles for shi-
kimate were generated using the Uppsala Software factory program
XPOL2D [15].
2.3. Model analysis and identiﬁcation of conformational changes
The MtSK ternary model was evaluated using PROCHECK [16],
which indicated that 93.3% of the ﬁnal model’s residues lie within themost favored regions of a Ramachandran plot and 6.7% within the
additionally allowed regions [17].
To compare diﬀerent SK complexes, the structures were overlaid
using TOP3D [18]. Ca torsion angles for each residue ‘i’, deﬁned as
the dihedral angle Caði 1Þ–CaðiÞ–Caðiþ 1Þ–Caðiþ 2Þ, were exam-
ined for each MtSK complex according to the methods described by
Flocco & Mowbray [19]. Torsion angle diﬀerences (TAD) between
the binary and ternary complexes were plotted using an EXCEL
macro as ([TAD]/2 SD)2, allowing signiﬁcant TAD peaks to be ob-
served clearly above the noise. The locations of hinges were found
using the TCL script HINGEFIND [20] (partition value¼ 0.5 and
maximum domains¼ 4), run and visualized with the graphics package
VMD [21].3. Results and discussion
3.1. The crystal structure
The overall MtSK structure consists of a central ﬁve-stran-
ded parallel b-sheet surrounded by eight helices [8]. As with
most SKs, the enzyme belongs to the family of nucleoside
monophosphate kinases [1,22], (Archea SKs, however, belong
to the GHMP-kinase family [23]). MtSK consists of three
domains: (1) the CORE domain containing the ﬁve stranded
parallel b-sheet and the P-loop (residues 9–17), which forms
the binding site for nucleotides; (2) the LID domain (residues
Gly112 to Asp124), which closes over the active site and has
residues that are essential for the binding of ATP; (3) the
substrate binding (SB) domain (residues Thr33 to Glu61),
which functions to recognize and bind shikimate. See [6,8,24]
for further details.
The MtSK dead end ADP-shikimate ternary complex
structure (this paper) consists of residues 2–166 with residues
114–115 removed from the model. Electron density for the ﬁrst
N-terminal residue was not observed, and residues 114–115
and the C-terminal residues 167–173 appear to be disordered.
The model also contains 3 chloride ions, 119 water molecules,
1 ADP molecule and 1 shikimate molecule. The binding mode
of ADP toMtSK in the ternary complex is essentially the same
as that reported by Gu et al. [8] for the binary complex.
3.2. Shikimate binding
Unambiguous diﬀerence electron density for a shikimate
molecule was found in a region corresponding to the NMP
binding site in NMP kinases near a-helices a2, a3 and the N-
terminal end of a4 (Fig. 1A). The binding of shikimate in a
crystal structure of a shikimate kinase, which should be of
importance in the development of inhibitors against the en-
zyme, has not been previously reported.
The shikimate binding site is characterized by a generally
hydrophobic surface together with a number of charged resi-
dues which project into the cavity. The lipophilic part of the
pocket is formed by Pro11 (part of the P-loop), and the highly
conserved residues Phe49, Phe57, Gly79, Gly80, Gly81, Pro118
and Leu119. The phenyl rings of Phe49 and Phe57 are sepa-
rated by 4.5 A and are orientated such that a weak ring
stacking interaction is formed.
Shikimate makes several key interactions with highly
conserved residues within the binding pocket (Fig. 1A): (1)
The carboxylate group of the shikimate forms strong hy-
drogen bonds and a salt-bridge with the guanidinum group
of Arg136; (2) The carboxylate group of Asp34 forms an-
other bidentate H-bond with the O12 hydroxyl group of
shikimate (the shikimate atom label nomenclature is shown
Fig. 1. The shikimate molecule. (A) Stereo diagram showing the Fo  Fc annealed electron density map with shikimate omitted, contoured at 4.5r.
Also shown are the main interactions between the substrate, ordered water molecules and MtSK. The ﬁgure was prepared using CNS [13], BOB-
SCRIPT [25] and Raster3D [26]. (B) Atom nomenclature for shikimate [27].
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with the O2 atom group of the substrate; (4) The main-chain
nitrogen of Gly80 interacts with the O11 hydroxyl group of
shikimate.
Other highly conserved residues are observed to interact
indirectly with the shikimate molecule: (1) Glu61 does not
bind to the substrate directly as previously suggested [6],
instead it interacts with the O12 hydroxyl of shikimate via a
bridging water molecule,W1, which forms a 2.6 A H-bond
with the OE2 group of Glu61; (2) The main-chain nitrogen
of Leu119 forms a 2.9 A H-bond with the W3 oxygen atom,
which in turn interacts with the O7 hydroxyl of shikimate;
(3) the NZ atom of Lys15 forms a 2.6 A H-bond with the
oxygen atom of W2, which also interacts with the O11 hy-
droxyl of the substrate. Lys15 does not form a H-bond di-
rectly with shikimate, as previously suggested from a
computational model of a MgADP-shikimate MtSK complex
[28]. Furthermore, the hypothetical model of MtSK does not
implicate Arg58, Glu61, Gly80 or Leu119 as being involved
in shikimate binding to MtSK as shown in this current work.
The bridging water molecules in the active site are also
present in the MtSK binary complex [8]. A detailed list of
contacts made between the shikimate molecule and MtSK
can be found in Table 2.All of the interactions described above serve to position and
orientate the O11 hydroxyl of the shikimate molecule ready for
nucleophilic attack by the c-phosphate of ATP.
3.3. Substrate induced conformational changes
In order to prevent unwanted ATP hydrolysis in the ab-
sence of substrate, kinases disassemble in the active site. The
repositioning of catalytically critical residues is an induced
ﬁt movement resulting from the binding of substrate
[6,24,29–33].
Previous studies have shown that adenylate kinases undergo
a large conformational change during catalysis [31,34]. More
recent reports have shown that conformational changes also
occur in shikimate kinases during the catalytic cycle. Thus,
circular dichroism studies have shown that ErcSK undergoes
large conformational changes on the addition of ATP analogs
or shikimate [6]. Indeed, a comparison of the apo ErcSK and
ADP binary MtSK structures has been used to suggest that
signiﬁcant conformational changes occur upon nucleotide
binding [8]. It was proposed that ADP binding induces a large
hinged movement of the LID domain over the active site,
bringing Arg110 and Arg117 into positions essential for in-
teraction with the nucleotide and about a 5 A repositioning of
the SB domain is observed.
Table 2
Interactions between MtSK and shikimate
Shikimate atom MtSK/water atom Distance (A)
C1 Gly81 N 3.3
Arg136 NH1 3.4
Arg136 NH2 3.5
Wat5 O 3.6
C4 Wat1 O 3.5
Wat3 O 3.5
C5 Wat1 O 3.4
Wat3 O 3.5
C8 Asp34 OD2 3.4
Asp34 CG 3.6
Asp34 OD1 3.2
C9 Asp34 OD2 3.6
C10 Gly80 N 3.4
O2 Gly81 N 3.5
Gly81 CA 3.5
Arg136 CZ 3.5
Arg136 NH1 3.5
Arg136 NH2 2.8
Arg58 NH2 2.6
Leu119 CD1 3.1
O3 Pro11 CG 3.5
Gly80 C 3.5
Gly81 N 3.4
Arg136 CZ 3.3
Arg136 NH1 2.5
Arg136 NH2 3.4
Wat5 O 3.2
O7 Wat3 O 3.0
O11 Asp34 OD2 2.7
Gly80 N 3.2
Wat2 O 2.9
Wat6 O 3.2
O12 Asp34 OD2 3.1
Asp34 CG 3.2
Asp34 OD1 2.6
Gly79 CA 3.5
Wat1 O 2.5
The distances were determined using the CONTACT program [18]
with 0–3.6 A distance limits.
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MtSK complexes, the binary complex MtSK-ADP structure
was overlaid onto the ternary structure. A root-mean-square
(rms) deviation of 0.7 A for 164 pairs of Ca atoms (excluding
residues 114–115) was calculated. The overlays were examined
in O and it was found that the central CORE domains su-
perimposed extremely well. When the Ca atoms of just the
CORE domains were overlaid, the rms deviation was only 0.2
A. However, conformational changes in the LID and SB do-
mains were observed (Fig. 2). Overlaying the Ca atoms of just
the LID (excluding residues 114–115) and SB domains from
the two MtSK structures, the rms deviations were 1.5 and 0.4
A, respectively. The conformational changes were further ex-
amined using TAD analysis.
During TAD analysis conformational changes can some-
times be diﬃcult to resolve from the background ‘noise’,
which can be attributed to coordinate error, diﬀerences in
structure resolution, crystal contacts or ﬂexible loops [19,35].
As the crystal contacts in the binary and ternary MtSKcomplex structures are essentially the same, these would have
negligible eﬀect on the TADs in this instance. MtSK contains
a large proportion of ﬂexible loops which were initially re-
moved in the TAD analysis to give a mean background of 3.
When the TAD analysis used the complete structures, the
peaks could easily be resolved from background noise
(Fig. 3). Analysis of the TAD plot and visualisation of the
MtSK models in VMD reveals that the movement of the
peripheral SB and LID domains is controlled by two inde-
pendent hinges [32]: (1) the SB hinge, involving a 10 counter-
rotation of the SB and CORE domains about axis H1, with
hinge points at Thr33 (HP1) and Gln55 (HP2) and (2) the
LID hinge, involving a 6 counter-rotation of the LID and
CORE domains about axis H2, with hinge points at Thr111
(HP3) and Pro123 (HP4). The net result is the movement of
the SB and LID domains towards the bound shikimate
(Fig. 2).
Shikimate binding induces domain closure, with the SB and
LID domains moving inwards to complete the catalytically
competent active site. It is unclear, however, whether the
movements occur in a deﬁned sequence or simultaneously.
Combining the HINGEFIND data with TAD analysis of the
binary and ternary models allows the identiﬁcation of struc-
tural changes from four hinge points associated with a-helices
a2, a4, a6 and a7.
When compared to the binary complex, the SB and LID
domain movements in the ternary structure result in several
key changes near the active site. Within the SB region, resi-
due Arg58 is shifted 0.9 A towards the carboxylate group of
shikimate. Phe49 moves 1.7 A away from Phe57 and closer
to the substrate. Phe57 translates towards the shikimate (with
the CZ atom moving 1.2 A) (Fig. 2B). The changes in the
orientation and positions of phenylalanines 49 and 57 disrupt
their strong ring stacking interactions and probably result
from the van der Waals contacts of shikimate with both
phenylalanines. In the LID domain, the sidechain of Arg117
is slightly reoriented (Fig. 2C), resulting in an H-bond of 2.6
A in length between the oxygen atom of water molecule 6
and the NE atom of Arg117 (W6 also forms a 3.2 A H-bond
with the O11 hydroxyl of shikimate). Arg136 becomes more
ordered in the ternary complex, adopting a single confor-
mation that interacts with the shikimate carboxyl group,
whilst in the binary complex with ADP it adopts two con-
formations.
The detailed stereochemistry of shikimate binding to MtSK
is revealed from the crystal structure reported here. The
identiﬁcation of domain and loop closure in MtSK associated
with shikimate binding demonstrates the importance of an
experimentally determined structure, since signiﬁcant diﬀer-
ences from the earlier docking studies of shikimate binding to a
model of MtSK [28] have been shown. Knowledge of confor-
mational changes resulting from substrate binding is clearly
important in the use of structure based approaches to design
novel inhibitors of the enzyme targeting the shikimate binding
site. It is hoped that such inhibitors will eventually give rise to
new anti-mycobacterial drugs.4. PDB accession number
Coordinates have been deposited in the PDB with the ac-
cession code 1U8A.
Fig. 2. The superimposed binary and ternary complexes of MtSK. (A) Cartoon representation of the overall structure of MtSK indicating the three
domains; CORE, SB and LID, secondary structure elements, loop regions and bound ligands. The four pivot points, HP1-HP4, associated with shi-
kimate inducedconformational changes inSKaremarked. (B) and (C)Tube representationsof theMtSKSBandLIDdomainoverlays, respectively. The
binary and ternaryMtSK structures are colored blue and green, respectively, except for the conformational diﬀerences in the SB and LID regions of the
binary and ternary complexes, which are colored red and pink, respectively. The ADPmolecules bound in the binary and ternary complexes are colored
yellow and orange, respectively. (Residues 114–115 are excluded from the ternary complex.) The ﬁgures were prepared using VMD [21].
Fig. 3. Torsion angle diﬀerence plot for MtSK between the binary and ternary complexes. The signiﬁcant TAD peaks are labeled: SB, SB domain;
LID, LID domain; L1, N-terminal loop; PL, P-loop connecting b1 to a1; L2, loop connecting a1 to b2; L3, loop connecting b2 to a2; L4, loop
connecting b4 to a6; L5, C-terminal loop; Ex, Ala134 on the exterior of protein; Hy, Hydrophobic loop. The 4 hinge points are labeled HP1–HP4.
Also depicted below the x-axis are the secondary structural elements of MtSK.
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